Agile Therapeutics Inc (fka AGRX)

[bUrRpPPP!]

The two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane should put that aspect of manufacture issues to rest,,, but I would still have liked more convincing theories as to how Twirla is going to complete with Ortho's Evra and generic name Xulane. Unless there is some giant advantage from switching from one patch to another It would be hard to change a womens routine just "because". Doctors would also have to be on board with such thinking as well... Ortho's army of local rep's likely have secured relationships with the local doctor's via Superbowl tickets etc wink wink...would be hard for a "one drug" company to ever change that...

Approval is one thing...sales are another.. all responses welcome!